Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Dana-Farber Cancer Institute, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:ChemotherapyHospital:Dana-Farber Cancer Institute
Drugs:Journal:Link
Date:Feb 2008

Description:

Patients: This phase II study involved 34 men with metastatic hormone-refractory (not responding to this type of treatment) prostate cancer. These patients were also refractory to docetaxel. The median age was 67.7, ranging from 46.7 to 81 years of age.

Treatment: Patients were treated with the chemotherapy drugs docetaxel and carboplatin.

Toxicity: One patient died while on the study, but this was not attributed to the treatment. Grade 3 leukopenia was reported in 56% of patients, and grade 4 neutropenia was reported in 21% of patients.

Results: The median overall survival was 12.4 months (from the time the patients were enrolled in this study).

Support: This study was supported by Bristol-Myers Squibb, which markets carboplatin as Paraplatin“.

Correspondence: Dr. William K. Oh



Back